IGFBP7 and acute kidney injury: Similar to our findings, one study demonstrated that when u[TIMP-2]*[IGFBP7] and uKIM-1 were combined, the AUC for AKI progression increased slightly from 0.745 to 0.752 and for AKI progression with mortality from 0.777 to 0.782 when compared to u[TIMP-2]*[IGFBP7] alone [9].